MarginsXMarginsX
Home › Markets › Health Care › BCYC

Bicycle Therapeutics plc (BCYC)

BCYC trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.18
-5.64% on the day
Market cap
$222.9M
Micro cap
Revenue · 2025
$72.6M
+105.8% on 2024
Net income · 2025
-$219.0M
-301.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1761612/000110465926028971/0001104659-26-028971-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBCYC on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited Kingdom
IPO year2019
SEC CIK0001761612
SEC industry codePharmaceutical Preparations
Incorporated inUnited Kingdom

Financials · 2025

LineValue
Revenue$72.6M
Net income-$219.0M
Operating income-$247.1M
Net margin-301.7%
Operating margin-340.4%
Revenue growth+105.8%
Cash$628.1M
Total assets$717.6M
P/E (computed)Net income was not positive
P/S (computed)3.1×

Warning signs

Cash runway
32.2 months
$469.9M cash at September 30, 2026
Share count, 1 year
+1.0%
2025-10-31 to 2026-10-31
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$543K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$469.9M cash; operating cash flow -$43.8M a quarter.Report 2026-09-30
Shares outstanding70,093,761 (2026-10-31); 69,367,896 a year earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, Cambridge, United KingdomPCAOB Form AP 2026-04-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $543K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$34.1M-$10.5M-$40.3M$469.9MNo debt tags$83.5M10-Q 2026-10-29
Q2 2026
2026-06-30
$629K-$50.3M-$49.6M$510.1MNo debt tags$61.2M10-Q 2026-07-30
Q1 2026
2026-03-31
$887K-$60.8M-$65.9M$559.5MNo debt tags$63.5M10-Q 2026-04-30
Q4 2025
2025-12-31
$48.0M-$20.2M-$19.3M$628.1MNo debt tags$72.6M10-K 2026-03-17
Q3 2025
2025-09-30
$11.7M-$59.1M-$71.2M$648.3MNo debt tags$28.3M10-Q 2026-10-29
Q2 2025
2025-06-30
$2.9M-$79.0M-$72.8M$721.5MNo debt tags$19.3M10-Q 2026-07-30
Q1 2025
2025-03-31
$10.0M-$60.8M-$86.4M$793.0MNo debt tags$25.7M10-Q 2026-04-30
Q4 2024
2024-12-31
$3.7M-$51.9M-$9.4M$879.5MNo debt tags$35.3M10-K 2026-03-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B32025-08-14
Latest annual report10-K2026-03-17
Latest quarterly / interim10-Q2026-10-29
Latest current report
FORM 8-K
8-K2026-10-29
Latest proxyDEF 14A2026-04-22

Source: SEC EDGAR submissions feed, 661 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.6%
1 month-7.2%
3 months-15.3%
Year to date-52.4%
1 year-48.9%
From 52-week high-55.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
DRUGBright Minds Biosciences Inc.$22.61-2.16%$222.0M
IMRXImmuneering Corporation$3.52-5.12%$228.0M
VNDAVanda Pharmaceuticals Inc.$3.81-4.51%$230.4M
VOGXVogenx Inc$14.38-13.74%$213.6M
AMRNAmarin Corporation plc$11.31-0.62%$233.4M
ACIUAC Immune SA$2.09-1.88%$212.7M
YARWYarrow Bioscience Inc.$13.93-22.74%$212.2M
CYPHCypherpunk Technologies Inc.$1.93+2.94%$207.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier